Fly News Breaks for March 2, 2015
MNKD
Mar 2, 2015 | 19:58 EDT
Goldman Sachs downgraded MannKind to Sell citing difficult pricing and slower diabetes product launches, particularly for Afrezza. The firm lowered its price target on MannKind's shares to $3 from $6.
News For MNKD From the Last 2 Days